Establishment and validation of a risk prediction model incorporating concentrations of linezolid and its metabolite PNU142300 for linezolid-induced thrombocytopenia
Journal of Antimicrobial Chemotherapy · 2023
DOI: 10.1093/jac/dkad191 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Jinhui Xu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, No. 26 Daoqian Street, Gusu District…. Hauptthemen laut MEDLINE: Thrombocytopenia, Renal Insufficiency. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Suzhou Science and Technology Project, Jiangsu Pharmaceutical Association, Hospital Pharmacy Research Project.
Abstract (Originalsprache)
Background
Linezolid-induced thrombocytopenia is the main factor restricting the clinical application of linezolid.
Objectives
To investigate the relationship between PNU-14230 concentration and linezolid-induced thrombocytopenia and further develop and validate a risk model for predicting linezolid-induced thrombocytopenia.
Methods
A regression model was constructed to predict the occurrence of linezolid-induced thrombocytopenia, and further externally validated. The predictive performance was evaluated by receiver operating characteristic curve and Hosmer–Lemeshow test. Linezolid Cmin and PNU-142300 concentrations were compared for different kidney function groups. The Kaplan–Meier method was used to estimate the difference in cumulative incidence of linezolid-induced thrombocytopenia among different kidney function patients.
Results
In the derivation (n = 221) and validation (n = 158) cohorts, 28.5% and 24.1% of critically ill patients developed linezolid-induced thrombocytopenia. Logistic regression analysis indicated that the independent risk factors were linezolid Cmin, PNU-142300 concentration, baseline platelet count, renal insufficiency (RI) and continuous venovenous haemofiltration (CVVH). The AUC for the risk model was 0.901, and the model was good (P = 0.633). The model also showed good discrimination (AUC 0.870) and calibration (P = 0.282) in the external validation cohort. Compared with normal kidney function patients, patients with RI and CVVH had higher linezolid Cmin and PNU-142300 concentrations (P < 0.001) and higher cumulative incidence of linezolid-induced thrombocytopenia (P < 0.001).
Conclusions
PNU142300 concentration, as well as linezolid Cmin, might identify patients at risk of linezolid-induced thrombocytopenia. The risk prediction model had good predictive performance for linezolid-induced thrombocytopenia development. Concentrations of linezolid and PNU-142300 accumulated in patients with RI and CVVH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, No. 26 Daoqian Street, Gusu District, Jiangsu 215002, Suzhou, China.
- Intensive Care Unit, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, China.
- Medical Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, China.
- Emergency Intensive Care Unit, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, China.
- Gusu School, Nanjing Medical University, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, China.
Förderung
- Suzhou Science and Technology Project
- Jiangsu Pharmaceutical Association
- Hospital Pharmacy Research Project
- Jiangsu Research Hospital Association for Precision Medication
- Wu Jieping Medical Foundation
- Gusu Talent Program
- Collaborative Innovation Project of Gusu School of Nanjing Medical University
Zitieren
APA
Xu, J., Lu, J., Yuan, Y., Duan, L., Shi, L., Chen, F., Cao, Y., Xu, G., Feng, Z., Li, L., Xue, H., Sun, J., Zhou, Q., Zhuang, Z., & Tang, L. (2023). Establishment and validation of a risk prediction model incorporating concentrations of linezolid and its metabolite PNU142300 for linezolid-induced thrombocytopenia. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad191
Vancouver
Xu J, Lu J, Yuan Y, Duan L, Shi L, Chen F, et al. Establishment and validation of a risk prediction model incorporating concentrations of linezolid and its metabolite PNU142300 for linezolid-induced thrombocytopenia. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad191
BibTeX
@article{Xu2023,
author = {Xu, Jinhui and Lu, Jian and Yuan, Yunlong and Duan, Lufen and Shi, Lu and Chen, Fang and Cao, Yifei and Xu, Guangjuan and Feng, Zongtai and Li, Lan and Xue, Hongzhi and Sun, Jiantong and Zhou, Qin and Zhuang, Zhiwei and Tang, Lian},
title = {Establishment and validation of a risk prediction model incorporating concentrations of linezolid and its metabolite PNU142300 for linezolid-induced thrombocytopenia},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2023},
doi = {10.1093/jac/dkad191}
}
EUVIMED